| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 5.8 | 7.0 | 4.2 |
| Other income | 0.0 | 0.2 | 0.0 |
| Total income | 5.8 | 7.1 | 4.2 |
| Profit before exceptional items & tax | -5.4 | -2.5 | -6.1 |
| Profit before tax | -5.4 | -2.5 | -6.1 |
| Net profit | -5.4 | -2.5 | -6.1 |
| Operating margin | -93.1% | -35.2% | -145.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +38.10% |
|---|---|
| Operating profit, year on year | +11.50% |
| Operating profit, quarter on quarter | -100.00% |
BSE results filing, NSE: KREBSBIO. Figures extracted from the filing.
Krebs Biochemicals & Industries Ltd: key numbers
- Share price
- ₹59.00
- Market cap
- ₹127.2 Cr
- Revenue (annual)
- ₹23.73 Cr
- Net profit (annual)
- ₹-16.93 Cr
- P/E (TTM)
- -9.0×Sector 46.1×
- Promoter holding
- 72.74%+0.00% QoQ
- FII holding
- 0.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Krebs Biochemicals & Industries Ltd
All →Krebs Biochemicals & Industries Board Meeting Date
Krebs Biochemicals & Industries Limited has scheduled a board meeting for October 29, 2026. The board will consider and adopt unaudited financial results for the second quarter.
Krebs Biochemicals & Industries Other Announcement
Krebs Biochemicals & Industries Ltd filed its quarterly shareholding pattern as mandated by SEBI regulations, disclosing the distribution of equity stakes among shareholders.
Krebs Biochemicals & Industries Annual General Meeting
Krebs Biochemicals & Industries Limited conducted its 34th Annual General Meeting on September 29, 2026. Shareholders considered the adoption of FY2025-26 audited financials and related party transactions.
Krebs Biochemicals & Industries Annual General Meeting
Krebs Biochemicals and Industries Limited has issued a notice for its 34th Annual General Meeting scheduled for September 29, 2026. Key agenda items include the approval of financial statements and related party transactions.
Krebs Biochemicals & Industries Annual Report
Krebs Biochemicals & Industries Limited has submitted its 34th Annual Report for the financial year 2025-26. The report includes financial highlights, directors' report, and audited financial statements.
Krebs Biochemicals & Industries Q1 FY27 Results: Net Loss of ₹2.5 Cr, Loss Narrows
Krebs Biochemicals & Industries Ltd reported revenue from operations of ₹7 Cr (+27.3% YoY) and a net loss of ₹2.5 Cr for Q1 FY27.
- Key figure
- Net loss ₹2.5 Cr